Table 4.
Select Ongoing Clinical Trials in HER2 exon 20 mutation NSCLC patients.VI. Conclusion.
| Drug | Mechanism of Action | Development Phase | Sponsor | NCT Number |
|---|---|---|---|---|
| Trastuzumab Deruxtecan | ADC | phase III (DESTINY-Lung04) | AstraZeneca | NCT05048797 |
| Pertuzumab + Trastuzumab + Docetaxel | Monoclonal antibody | phase II | Intergroupe Francophone de Cancerologie Thoracique | NCT03845270 |
| Pyrotinib | TKI | phase III (PYRAMID-1) | Jiangsu HengRui Medicine Co | NCT04447118 |
| Pyrotinib + Thalidomide | TKI | phase II | Shanghai Chest Hospital | NCT04382300 |
| Pyrotinib | TKI | phase II | Tianjin Medical University Cancer Institute and Hospital | NCT04063462 |
| Poziotinib | TKI | phase III (PINNACLE) | Spectrum Pharmaceuticals | NCT05378763 |
| Poziotinib | TKI | phase II | MD Anderson Cancer Center | NCT03066206 |
| Poziotinib | TKI | phase II | Spectrum Pharmaceuticals | NCT03318939 |
| Mobocertinib | TKI | phase I/II | Takeda | NCT02716116 |
| BDTX-189 (tuxobertinib) | TKI | phase I/II(MasterKey-01) | Black Diamond Therapeutics | NCT04209465 |
| DZD9008 (sunvozertinib) | TKI | phase I/II (WU-KONG1) | Dizal Pharmaceuticals | NCT03974022 |
| AST2818 (furmonertinib) | TKI | phase I | ArriVent BioPharma | NCT05364073 |
| BAY2927088 | TKI | phase I | Bayer | NCT05099172 |